151751-Najiba-Chargi

281 Systemic therapy: skeletal muscle mass changes and chemoradiotherapy Table 3. Characteristics of patients with stable SMM versus patients with loss and gain of SMM Characteristic Stable n=91 41.2% Muscle Loss N=130 90.3% Muscle Gain N=14 9.7% p N (%) N (%) N (%) Gender Male Female 63 (69.2) 28 (30.8) 89 (68.5) 41 (31.5) 12 (85.7) 2 (14.3) 0.4 Age >60 years No Yes 45 (49.5) 46 (50.5) 72 (55.4) 58 (44.6) 7 (50) 7 (50) 0.7 BMI (kg/m 2 ) <18.5 18.5-24.9 25.0-29.9 ≥ 30 14 (15.4) 50 (54.9) 19 (20.9) 8 (8.8) 6 (4.6) 60 (46.2) 40 (30.8) 24 (18.5) 7 (50) 1 (7.1) 6 (42.9) 0 (0) 0.01 ACE-27 score None Mild Moderate Severe 18 (19.8) 48 (52.7) 19 (20.9) 6 (6.6) 29 (22.3) 64 (49.2) 30 (23.1) 7 (5.4) 3 (21.4) 3 (21.4) 4 (28.6) 4 (28.6) 0.7 Performance ECOG 0 ECOG 1 ECOG ≥2 Unknown 24 (26.4) 48 (52.7) 8 (8.8) 11 (12.1) 37 (28.5) 53 (40.8) 19 (14.6) 21 (16.2) 2 (14.3) 10 (71.4) 0 (0) 2 (14.3) 0.2 Smoking No Former Current 18 (19.8) 25 (27.5) 48 (52.7) 24 (18.5) 37 (28.5) 69 (53.1) 1 (7.1) 3 (21.4) 10 (71.4) 0.7 Alcohol use No Current/former 18 (19.8) 73 (80.2) 2 (14.3) 12 (85.7) 20 (15.4) 110 (84.6) 0.7 Tumor site Oral cavity Oropharynx Nasopharynx Hypopharynx Larynx Paranasal sinus Unknown primary 30 (33) 22 (24.2) 9 (9.9) 16 (17.6) 4 (4.4) 3 (3.3) 7 (7.7) 46 (35.4) 46 (35.4) 10 (7.7) 14 (10.8) 6 (4.6) 7 (5.4) 1 (0.8) 7 (50) 5 (35.7) 0 (0) 2 (14.3) 0 (0) 0 (0) 0 (0) 0.2 TNM-stage III IV 14 (15.4) 77 (84.6) 26 (20) 104 (80) 0 (0) 14 (100) 0.3 Legend table 3: p-values printed in bold were significant at a 0.05 level. Abbreviations: SMM: skeletal muscle mass, BMI: body-mass index, ACE-27: adult comorbidity evaluation-27, ECOG: Easter Cooperative Oncology Group, HPV: human papilloma virus, TNM: tumor, node, metastasis 15